» Articles » PMID: 30185468

Human-Specific Abnormal Alternative Splicing of Wild-Type Induces Premature Termination of Polycystin-1

Overview
Specialty Nephrology
Date 2018 Sep 7
PMID 30185468
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The major form of autosomal dominant polycystic kidney disease is caused by heterozygous mutations in , the gene that encodes polycystin-1 (PC1). Unlike genes in the mouse and most other mammals, human is unusual in that it contains two long polypyrimidine tracts in introns 21 and 22 (2.5 kbp and 602 bp, respectively; 97% cytosine and thymine). Although these polypyrimidine tracts have been shown to form thermodynamically stable segments of triplex DNA that can cause DNA polymerase stalling and enhance the local mutation rate, the efficiency of transcription and splicing across these cytosine- and thymine-rich introns has been unexplored.

Methods: We used RT-PCR and Western blotting (using an mAb to the N terminus) to probe splicing events over exons 20-24 in the mouse and human genes as well as Nanopore sequencing to confirm the presence of multiple splice forms.

Results: Analysis of PC1 indicates that humans, but not mice, have a smaller than expected protein product, which we call Trunc_PC1. The findings show that Trunc_PC1 is the protein product of abnormal differential splicing across introns 21 and 22 and that 28.8%-61.5% of transcripts terminate early.

Conclusions: The presence of polypyrimidine tracts decreases levels of full-length mRNA from normal alleles. In heterozygous individuals, low levels of full-length PC1 may reduce polycystin signaling below a critical "cystogenic" threshold.

Citing Articles

Triplex H-DNA structure: the long and winding road from the discovery to its role in human disease.

Hisey J, Masnovo C, Mirkin S NAR Mol Med. 2024; 1(4):ugae024.

PMID: 39723156 PMC: 11667243. DOI: 10.1093/narmme/ugae024.


Prospects for gene therapy in polycystic kidney disease.

Chakraborty A, Yu A Curr Opin Nephrol Hypertens. 2024; 34(1):121-127.

PMID: 39499052 PMC: 11606769. DOI: 10.1097/MNH.0000000000001030.


Fibrocystin/Polyductin releases a C-terminal fragment that translocates into mitochondria and suppresses cystogenesis.

Walker R, Yao Q, Xu H, Maranto A, Swaney K, Ramachandran S Nat Commun. 2023; 14(1):6513.

PMID: 37845212 PMC: 10579373. DOI: 10.1038/s41467-023-42196-4.


Allele-specific quantification of human leukocyte antigen transcript isoforms by nanopore sequencing.

Hughes A, Montgomery M, Liu C, Weimer E Front Immunol. 2023; 14:1199618.

PMID: 37662944 PMC: 10471969. DOI: 10.3389/fimmu.2023.1199618.


Atypical splicing variants in PKD1 explain most undiagnosed typical familial ADPKD.

Hort Y, Sullivan P, Wedd L, Fowles L, Stevanovski I, Deveson I NPJ Genom Med. 2023; 8(1):16.

PMID: 37419908 PMC: 10328916. DOI: 10.1038/s41525-023-00362-z.


References
1.
Rossetti S, Consugar M, Chapman A, Torres V, Guay-Woodford L, Grantham J . Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007; 18(7):2143-60. DOI: 10.1681/ASN.2006121387. View

2.
Ong , Harris , Biddolph , Bowker , Ward . Characterisation and expression of the PKD-1 protein, polycystin, in renal and extrarenal tissues. Kidney Int. 1999; 55(5):2091-2116. DOI: 10.1046/j.1523-1755.1999.00404.x. View

3.
Rossetti S, Hopp K, Sikkink R, Sundsbak J, Lee Y, Kubly V . Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012; 23(5):915-33. PMC: 3338301. DOI: 10.1681/ASN.2011101032. View

4.
Qian F, Watnick T, Onuchic L, Germino G . The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell. 1996; 87(6):979-87. DOI: 10.1016/s0092-8674(00)81793-6. View

5.
Blaszak R, Potaman V, Sinden R, Bissler J . DNA structural transitions within the PKD1 gene. Nucleic Acids Res. 1999; 27(13):2610-7. PMC: 148468. DOI: 10.1093/nar/27.13.2610. View